EP Patent

EP1043977A1 — Oral pharmaceutical pulsed release dosage form

Assigned to AstraZeneca AB · Expires 2000-10-18 · 26y expired

What this patent protects

An enteric coated pharmaceutical dosage form comprising a H+, K+-ATPase inhibitor. The dosage form comprises at least two portions of the H+, K+-ATPase inhibitor to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pu…

USPTO Abstract

An enteric coated pharmaceutical dosage form comprising a H+, K+-ATPase inhibitor. The dosage form comprises at least two portions of the H+, K+-ATPase inhibitor to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pulsed delayed release and another fraction with instant release of the H+, K+-ATPase inhibitor. The portions are released in time by from 0.5 and up to 12 hours interval, preferably by from 0.5 and up to 8 hours, and more preferably by from 0.5 and up to 4 hours interval. The dosage form is intended for once daily administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP1043977A1
Jurisdiction
EP
Classification
—
Expires
2000-10-18
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.